Sugi Predict

Sugi Predict / Targets / CES1

CES1

Liver carboxylesterase 1 · P23141 · CES1 on Sugi Atlas →

276,473 patent compounds predicted against CES1, 156,633 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Benzil Benzil (SCHEMBL66) 1.00 12/20
Benzoyl Formic Acid Benzoyl Formic Acid (SCHEMBL38943) 0.77 11/20
SCHEMBL42428 SCHEMBL42428 0.59 10/20
SCHEMBL36097 SCHEMBL36097 0.59 8/20
SCHEMBL21310 SCHEMBL21310 0.56 8/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL28875) 0.53 8/20
SCHEMBL7684 SCHEMBL7684 0.58 7/20
SCHEMBL15173 SCHEMBL15173 1.00 6/20
SCHEMBL8557 SCHEMBL8557 0.71 6/20
SCHEMBL25114 SCHEMBL25114 0.60 6/20
SCHEMBL32101 SCHEMBL32101 0.56 6/20
Enoxolone Enoxolone (SCHEMBL18539) 1.00 5/20
Enoxolone Enoxolone (SCHEMBL18540) 1.00 5/20
Enoxolone Enoxolone (SCHEMBL25465) 1.00 5/20
SCHEMBL29518 SCHEMBL29518 0.65 5/20
Methoxymethane Methoxymethane (SCHEMBL36163) 0.62 5/20
SCHEMBL22540 SCHEMBL22540 0.58 5/20
Benzoic Acid Benzoic Acid (SCHEMBL27621) 0.56 5/20
SCHEMBL39274 SCHEMBL39274 0.55 5/20
SCHEMBL24188 SCHEMBL24188 0.54 5/20

Clinical trials — most relevant to CES1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD PHASE4RECRUITING
CES1 Crossover Trial of Clopidogrel and Ticagrelor PHASE4COMPLETED
The Low HDL On Six Weeks Statin Therapy (LOW) Study PHASE4UNKNOWN
BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases PHASE2/PHASE3WITHDRAWN
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency PHASE2/PHASE3COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes PHASE3COMPLETED
A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism PHASE2COMPLETED
Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency PHASE1/PHASE2COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency PHASE2COMPLETED
Cholic Acid for Hepatic Steatosis in Lipodystrophy PHASE2COMPLETED
Alcohol Inhibits Drug Metabolism by Carboxylesterases PHASE1COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
The Relationship Between CES1 Genotype and Methylphenidate Response in Children With ADHD - INDICES Work Package 6 nanCOMPLETED
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype nanCOMPLETED
Lysosomal Acid Lipase (LAL) Deficiency Registry nanRECRUITING
Abnormal Lipids - Causes and Effects nanRECRUITING
Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL) nanCOMPLETED
Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease nanUNKNOWN
Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD) nanCOMPLETED
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors nanCOMPLETED
Use of MCT Oil for Enhancement of Weight Loss in Obese Patients nanCOMPLETED
Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV nanCOMPLETED
Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up) nanNOT_YET_RECRUITING
Paraoxonase and LDL Oxidation in Carotid Artery Disease nanCOMPLETED
Effects of Exercise on Fructose-induced Postprandial Lipemia nanCOMPLETED
Effects of Parenteral L-carnitine Supplementation in Premature Neonates nanCOMPLETED
Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study nanUNKNOWN
Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up) nanNOT_YET_RECRUITING
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CES1 binder may also engage these)

ProteinNameSimilarity
O46421 — 1.000 O46421 →
Q8VCC2 — 1.000 Q8VCC2 →
P10959 — 1.000 P10959 →
Q64176 — 1.000 Q64176 →
Q8VCT4 — 1.000 Q8VCT4 →
Q29550 — 1.000 Q29550 →
P23953 — 1.000 P23953 →
Q63010 — 1.000 Q63010 →
Q63108 — 1.000 Q63108 →
P12337 — 1.000 P12337 →
Q64573 — 1.000 Q64573 →
P16303 — 1.000 P16303 →
Q91WU0 — 1.000 Q91WU0 →
Q63880 — 1.000 Q63880 →
Q8K3R0 — 1.000 Q8K3R0 →
Q5GRG2 — 1.000 Q5GRG2 →
Q8R0W5 — 0.999 Q8R0W5 →
P0C6R3 — 0.999 P0C6R3 →
Q8VCU1 — 0.999 Q8VCU1 →
Q64419 — 0.997 Q64419 →
Q03311 — 0.997 Q03311 →
Q91WG0 — 0.996 Q91WG0 →
Q6NT32 — 0.996 Q6NT32 →
P32749 — 0.996 P32749 →
W4VSJ0 — 0.996 W4VSJ0 →
P30122 — 0.996 P30122 →
Q6AW46 — 0.996 Q6AW46 →
Q27677 — 0.996 Q27677 →
P04058 — 0.996 P04058 →
O62760 — 0.995 O62760 →